108552
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
内脏脂肪肝病患者的腰大肌指数、全身炎症与肝纤维化：一项病例对照研究
Authors Yu L, Jiang N, Wu H, Li J, Xu S
Received 10 February 2025
Accepted for publication 12 September 2025
Published 18 September 2025 Volume 2025:18 Pages 3527—3538
DOI https://doi.org/10.2147/DMSO.S521829
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Editor who approved publication: Professor Jae Woong Sull
Lijuan Yu,1 Nan Jiang,2 Huichun Wu,3 Jie Li,1 Shenjie Xu1
1Department of General Practice, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People’s Republic of China; 2Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China; 3Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People’s Republic of China
Correspondence: Shenjie Xu; Jie Li, Email xushenjie@suda.edu.cn; lijie@suda.edu.cn
Objective: Investigating psoas muscle index (PMI) as a potential biomarker for metabolic dysfunction-associated fatty liver disease (MAFLD) and hepatic fibrosis through a case-control study.
Methods: This case-control study enrolled 80 MAFLD patients and 80 healthy controls from our hospital (2023– 2024). Abdominal CT-derived PMI, inflammatory markers, and FIB-4 scores were assessed. ROC and logistic regression analyses evaluated PMI’s diagnostic potential for MAFLD and associated fibrosis.
Results: A total of 160 patients met the inclusion criteria. Compared with the non-MAFLD group, the PMI and systemic inflammatory indicators in the MAFLD group were higher. In MAFLD patients, PMI was significantly correlated with systemic inflammation indicators, including the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII) (P< 0.001, P=0.038, and P< 0.001, respectively). ROC curve analysis showed that the areas under the ROC curve (AUC) of PMI and other systemic inflammatory indicators (PLR, NLR, LMR, SII) for diagnosing MAFLD were 0.615, 0.526, 0.956, 0.803, and 0.674, respectively. The AUC of PMI combined with LMR, NLR, and LMR plus NLR for diagnosing MAFLD were 0.547, 0.585, and 0.572, respectively. FIB-4 was linearly correlated with PMI and systemic inflammatory indicators (PLR, NLR, SII) (r=− 0.208, P=0.008; r=− 0.211, P=0.007; r=0.327, P< 0.001; r=0.164, P=0.039). The combination of PMI and systemic inflammatory indicators (PLR, NLR, SII) demonstrated a good diagnostic ability for liver fibrosis in MAFLD (AUC=0.602, P=0.003).
Conclusion: PMI significantly correlates with systemic inflammation and hepatic fibrosis in MAFLD patients, serving as a diagnostic biomarker. Combined with inflammatory markers, it improves non-invasive screening efficacy for MAFLD/fibrosis. This study pioneers incorporating muscle metabolism into MAFLD diagnosis, with potential for primary care translation. Dynamic PMI monitoring may assess “muscle-liver axis” targeted therapies.
Keywords: psoas muscle index, systemic inflammation, liver fibrosis, fatty liver, metabolic dysfunction
1Department of General Practice, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People’s Republic of China; 2Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, People’s Republic of China; 3Department of Infectious Diseases, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People’s Republic of China
Correspondence: Shenjie Xu; Jie Li, Email xushenjie@suda.edu.cn; lijie@suda.edu.cn
Objective: Investigating psoas muscle index (PMI) as a potential biomarker for metabolic dysfunction-associated fatty liver disease (MAFLD) and hepatic fibrosis through a case-control study.
Methods: This case-control study enrolled 80 MAFLD patients and 80 healthy controls from our hospital (2023– 2024). Abdominal CT-derived PMI, inflammatory markers, and FIB-4 scores were assessed. ROC and logistic regression analyses evaluated PMI’s diagnostic potential for MAFLD and associated fibrosis.
Results: A total of 160 patients met the inclusion criteria. Compared with the non-MAFLD group, the PMI and systemic inflammatory indicators in the MAFLD group were higher. In MAFLD patients, PMI was significantly correlated with systemic inflammation indicators, including the platelet-to-lymphocyte ratio (PLR), neutrophil-to-lymphocyte ratio (NLR), and systemic immune-inflammation index (SII) (P< 0.001, P=0.038, and P< 0.001, respectively). ROC curve analysis showed that the areas under the ROC curve (AUC) of PMI and other systemic inflammatory indicators (PLR, NLR, LMR, SII) for diagnosing MAFLD were 0.615, 0.526, 0.956, 0.803, and 0.674, respectively. The AUC of PMI combined with LMR, NLR, and LMR plus NLR for diagnosing MAFLD were 0.547, 0.585, and 0.572, respectively. FIB-4 was linearly correlated with PMI and systemic inflammatory indicators (PLR, NLR, SII) (r=− 0.208, P=0.008; r=− 0.211, P=0.007; r=0.327, P< 0.001; r=0.164, P=0.039). The combination of PMI and systemic inflammatory indicators (PLR, NLR, SII) demonstrated a good diagnostic ability for liver fibrosis in MAFLD (AUC=0.602, P=0.003).
Conclusion: PMI significantly correlates with systemic inflammation and hepatic fibrosis in MAFLD patients, serving as a diagnostic biomarker. Combined with inflammatory markers, it improves non-invasive screening efficacy for MAFLD/fibrosis. This study pioneers incorporating muscle metabolism into MAFLD diagnosis, with potential for primary care translation. Dynamic PMI monitoring may assess “muscle-liver axis” targeted therapies.
Keywords: psoas muscle index, systemic inflammation, liver fibrosis, fatty liver, metabolic dysfunction